Some receptor tyrosine kinase inhibitors, such as gefitinib, afatinib, and anlotinib, can target the VEGFC-VEGFR3 signaling pathway, which potentially inhibits tumor-related lymphangiogenesis, lymphatic metastasis, and distant organ metastasis (75, 76). Here, VEGFC is linked to neoplasm.